Efficacy of favipiravir-based drugs against COVID-19 confirmed by clinical trials in Russia and Japan Avifavir already delivered to Belarus, Bolivia, Kazakhstan, Kyrgyzstan, Turkmenistan and Uzbekistan, deliveries to 17 more countries expected MOSCOW, Sept. 24, 2020 /PRNewswire/ — The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and ChemRar Group have agreed to supply Avifavir, […]

Read More

– Global landmark in the successful treatment of COVID-19 – Avifavir is the first direct-acting antiviral drug registered in Russia that has proven effective against COVID-19 in clinical trials – Avifavir has become the first Favipiravir-based drug in the world approved for the treatment of COVID-19 MOSCOW, June 1, 2020 /PRNewswire/ — The Russian Direct […]

Read More

MOSCOW, May 13, 2020 /PRNewswire/ — The Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, and the ChemRar Group today announce the positive first interim results of the multicenter randomized open comparative clinical trial of the drug Favipiravir on patients hospitalized with COVID-19. According to the data received, 60% of the 40 patients who […]

Read More